D
피씨엘
241820KOSDAQ37.5 / 100
Reference Date: 2026-09-08
Financial Score5.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
PCl focuses on developing pharmaceuticals, medical devices, and diagnostic technologies such as biochips and ELISA. The company specializes in advanced medical solutions, including hepatitis diagnostics, multiplex testing platforms, and genetic analysis.
Number of Employees
—
Average Salary
—
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
2.36Industry Average 1.201.0Point
2.0x industry avg (risky)
ROE
-236.30Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
203.20Industry Average 100.000.0Point
2.0x industry avg (risky)
Trend 2022~20240.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼81.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼81.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -146.6% (declining, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 6,040Won52-week high 6,04052-week low 6,040
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0